Grin2D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Glutamate Ionotropic Receptor NMDA Type Subunit 2D | |
|---|---|
| Gene Symbol | GRIN2D |
| Full Name | Glutamate Ionotropic Receptor NMDA Type Subunit 2D |
| Chromosomal Location | 19q13.1 |
| NCBI Gene ID | 2905 |
| OMIM | 604397 |
| Ensembl ID | ENSG00000105464 |
| UniProt ID | Q9H8A0 |
| Protein | NMDA Receptor Subunit GluN2D |
The GRIN2D gene encodes the GluN2D subunit of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptor critical for synaptic transmission, plasticity, and neuronal development. NMDA receptors are heteromeric complexes composed of GluN1 (encoded by GRIN1) and GluN2 (A-D) or GluN3 subunits. The GluN2D subunit confers distinct pharmacological and biophysical properties to NMDA receptors, including slower kinetics, reduced magnesium sensitivity, and unique agonist profiles. GRIN2D is expressed predominantly in subcortical brain regions, including the striatum, thalamus, brainstem, and during development, in the cerebral cortex. This subunit plays important roles in motor control, sensory processing, and cognitive functions. Dysregulation of GRIN2D has been implicated in various neurological and psychiatric disorders, including epilepsy, Parkinson's disease, Alzheimer's disease, and schizophrenia.
The GluN2D subunit is a transmembrane protein that forms the ligand-binding domain and the transmembrane domains of the NMDA receptor complex. When assembled with the obligatory GluN1 subunit, GluN2D forms functional NMDA receptors that respond to glutamate and glycine co-agonists. The properties of GluN2D-containing NMDA receptors differ from other GluN2 subunits:
GRIN2D-containing NMDA receptors are extrasynaptic in many brain regions, contributing to tonic NMDA receptor signaling rather than phasic synaptic transmission. These receptors play roles in rhythmic firing, sensory integration, and motor coordination.
GRIN2D mutations have been identified in patients with epileptic encephalopathies. De novo missense mutations can cause gain-of-function or loss-of-function effects, leading to hyperexcitability or impaired synaptic transmission. Mutations in GRIN2D are associated with early-onset seizures, developmental delay, and sometimes movement disorders. In animal models, altered GluN2D expression or function can affect seizure susceptibility.
GRIN2D may play a role in Parkinson's disease (PD) pathophysiology. Studies have shown altered GRIN2D expression in the basal ganglia of PD models and patients. NMDA receptors containing GluN2D subunits are highly expressed in the striatum, a region critically affected in PD. These receptors may contribute to excitotoxicity in dopaminergic neuron loss. Additionally, levodopa treatment can alter NMDA receptor subunit composition.
GRIN2D dysregulation has been reported in Alzheimer's disease brain. Changes in GluN2D expression may contribute to altered NMDA receptor signaling and calcium dyshomeostasis in AD. The subunit may be involved in the interaction between amyloid-beta pathology and glutamatergic signaling.
Genetic association studies have linked GRIN2D to schizophrenia risk. Altered expression and alternative splicing of GRIN2D has been observed in postmortem brain from schizophrenia patients. Given the role of NMDA receptors in synaptic plasticity and cognition, GRIN2D dysfunction may contribute to cognitive deficits in schizophrenia.
GRIN2D is a potential therapeutic target for various neurological conditions:
GRIN2D knockout mice are viable and show subtle behavioral phenotypes, including alterations in motor coordination and sensory processing. The mice exhibit changes in striatal synaptic plasticity and responses to dopaminergic manipulation. These models have been used to study the role of GluN2D in various neurological conditions.
The study of Grin2D Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Twomey EC, et al. (2017). The dynamic subunits of NMDA receptor subtypes. Neuropharmacology 112(Pt A):10-17. PMID:27461834
[2] Brickley SG, et al. (2001). NR2D: A pharmacological gateway to NMDA receptor function? Trends in Pharmacological Sciences 22(5):221-223. PMID:11340018
[3] Luo J, et al. (2017). GRIN2D mutations in epilepsy and neurodevelopmental disorders. Brain 140(9):e52. PMID:28633443
[4] Hillman BG, et al. (2011). NR2D-containing NMDA receptors in brain. Neuropharmacology 61(1-2):108-114. PMID:21396348
[5] Loftis JM, et al. (2003). NMDA receptor subunit diversity: Impact on receptor properties and synaptic plasticity. Neuropharmacology 45(6):719-736. PMID:14573381